COPD in young patients: A pre-specified analysis of the four-year trial of tiotropium (UPLIFT)

• Published in: Respiratory medicine 2010-11, Vol.104 (11), p.1659-1667
• Main Authors: Morice, A.H, Celli, B, Kesten, S, Lystig, T, Tashkin, D, Decramer, M
• Format: Article
• Language: English
• Subjects: Age; Biological and medical sciences; Bronchodilator Agents - therapeutic use; Chronic obstructive pulmonary disease; Chronic obstructive pulmonary disease, asthma; Disease Progression; Double-Blind Method; Drug therapy; Female; Forced Expiratory Volume - drug effects; Forced Expiratory Volume - physiology; Humans; Lung function; Male; Medical sciences; Middle Aged; Mortality; Pharmaceutical industry; Pneumology; Pulmonary Disease, Chronic Obstructive - drug therapy; Pulmonary Disease, Chronic Obstructive - mortality; Pulmonary Disease, Chronic Obstructive - physiopathology; Pulmonary/Respiratory; Quality of Life; Scopolamine Derivatives - therapeutic use; Surveys and Questionnaires; Tiotropium; Tiotropium Bromide; Treatment Outcome
• ISSN: 0954-6111; 1532-3064
• DOI: 10.1016/j.rmed.2010.07.016

Summary Whilst recent large-scale studies have provided much evidence on the natural history and therapeutic response in patients with chronic obstructive pulmonary disease (COPD), relatively little is known about the effect in younger patients. We report a pre-specified post-hoc analysis of 356 patients with COPD ≤ 50 years old from the four year randomised, double blind placebo controlled Understanding Potential Long Term Impact on Function with Tiotropium (UPLIFT) trial. Inclusion criteria included a post-bronchodilator forced expiratory volume in 1 s (FEV1 ) of ≤70%, FEV1 /FVC